Meeting the challenges of ambulatory surgery
ASCs are at the forefront of providing efficient, patient-centered care. However, they often encounter obstacles such as fluctuating costs, supply chain complexities and the need for specialized equipment and services. The Vizient orthopedic portfolio for ASC facilities is designed to meet these specific needs, ensuring that these facilities can continue offering exceptional care without compromising quality or financial stability.
Focus on orthopedics
Orthopedics is critical in ambulatory surgery, requiring the correct implant technology and surgical supplies. With access to best-in-class pricing on essential products in ten critical implant categories, orthopedic procedures can be performed with the highest standards of care, benefiting both patients and providers. By collaborating on a national scale, ASCs' aggregated volume can maximize their collective impact.
In the U.S., there are more than 6,000 Medicare-certified ambulatory surgery centers (ASCs), 85% which are physician or private equity owned. This market requires a standardized contracting portfolio that adapts to this evolving business model. Given the aging population, the shift in procedures to outpatient sites of care and decreasing reimbursements, it is crucial for the viability of ASCs to adopt a contracting strategy that emphasizes quality and cost efficiency.
This portfolio is designed to deliver unparalleled pricing advantages, helping ASCs manage their budgets more effectively. By leveraging the aggregation of our extensive network and negotiating power, ASCs can access products, ensuring they remain at the cutting edge of surgical care.
10 categories in the orthopedic portfolio
The Vizient non-acute orthopedic contracting portfolio will enable ASCs to improve bottom-line performance while ensuring contracted products support the highest quality of care.
- Spine, open and MIS
- Total joints hip and knee
- Total joint shoulder
- Bone cement
- Trauma
- Small joint
- VCF
- Arthroscopy
- Orthobiologics
- Neurostimulation
24%